Yesterday’s Capital Markets Day highlighted the successful re-positioning of the company over the past 18 months (including a strengthening of its management and development teams) and the liver-targeted GalNac-siRNA technology platform, with a particular focus on lead programmes SLN124 and SLN226 (INDs expected Q4 2018 and Q2 2019 respectively). A particularly interesting takeaway was the sustained duration of gene knockdown achievable through GalNAc mediated siRNA delivery, which bodes well for the broad utility of the platform.
